12亿美元!映恩生物牵手Avenzo,ADC市场激战愈酣

21世纪经济报道
09 Jan

2025年开年以来,ADC(抗体药物偶联物)市场依旧火爆,重磅交易热度不减。  1月8日,映恩生物宣布与Avenzo Therapeutics(下称“Avenzo”)签订一项独家许可协议,Avenzo将获得在全球范围内(大中华区除外)开发、制造和商业化DB-1418/AVZO-1418的独家权利。  DB-1418/AVZO-1418是映恩生物开发的EGFR/HER3双特异性ADC。根据协议,...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10